67 related articles for article (PubMed ID: 33607862)
1. Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study.
Jiang Y; Wang L; Dong Z; Xia B; Pang S
J Diabetes; 2024 Jun; 16(6):e13563. PubMed ID: 38783768
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol.
Peter EL; Deyno S; Mtewa A; Kasali FM; Nagendrappa PB; Sesaazi D; Tolo CU; Ogwang PE
Syst Rev; 2018 Nov; 7(1):192. PubMed ID: 30442186
[TBL] [Abstract][Full Text] [Related]
3. Clinical investigation of glucokinase activators for the restoration of glucose homeostasis in diabetes.
Li P; Zhu D
J Diabetes; 2024 May; 16(5):e13544. PubMed ID: 38664885
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials.
Wu Y; Wang K; Su J; Liu X
Medicine (Baltimore); 2024 Feb; 103(8):e36916. PubMed ID: 38394489
[TBL] [Abstract][Full Text] [Related]
5. Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far.
Kaur U; Pathak BK; Meerashahib TJ; Krishna DVV; Chakrabarti SS
Clin Drug Investig; 2024 Apr; 44(4):223-250. PubMed ID: 38460077
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic and antiosteoporotic pharmacotherapies for prevention and treatment of type 2 diabetes-induced bone disease: protocol for two network meta-analyses.
Deng J; Abbas U; Chang O; Dhivagaran T; Sanger S; Bozzo A
BMJ Open; 2020 Feb; 10(1):e034741. PubMed ID: 32014879
[TBL] [Abstract][Full Text] [Related]
7. Dorzagliatin for Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Phase II/III Trials.
Lin F; He R; Ling B; Wang L; Jiang T; Yu B
Clin Ther; 2023 Dec; 45(12):1277-1283. PubMed ID: 37777375
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of walking exercise on glycemic control in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis of randomized cross-over controlled trials.
Hu H; Lei Y; Yin L; Luo X
Medicine (Baltimore); 2020 Nov; 99(47):e22735. PubMed ID: 33217794
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus.
Peter EL; Mtewa AG; Nagendrappa PB; Kaligirwa A; Sesaazi CD
Syst Rev; 2020 Jan; 9(1):7. PubMed ID: 31915054
[TBL] [Abstract][Full Text] [Related]
10. New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment.
Haddad D; Dsouza VS; Al-Mulla F; Al Madhoun A
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203742
[TBL] [Abstract][Full Text] [Related]
11. The effect of health-care Qigong Baduanjin combined with auricular point sticking on athletes' pre-competition anxiety: A protocol for systematic review and meta-analysis.
Li L; Li X; Xie P; Li Y; Ma L; Ding B
Medicine (Baltimore); 2021 Feb; 100(7):e24874. PubMed ID: 33607863
[TBL] [Abstract][Full Text] [Related]
12. Silver dressing in the treatment of diabetic foot: A protocol for systematic review and meta-analysis.
Huang C; Wang R; Yan Z
Medicine (Baltimore); 2021 Feb; 100(7):e24876. PubMed ID: 33607864
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of non-surgical periodontal treatment on glycaemic control in patients with diabetes with periodontitis: a systematic review and meta-analysis protocol.
Ndjidda Bakari W; Diallo AM; Danwang C; Nzalie RNT; Benoist HM
BMJ Open; 2021 Feb; 11(2):e043250. PubMed ID: 33619190
[TBL] [Abstract][Full Text] [Related]
14. Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states.
Bahl V; Lee May C; Perez A; Glaser B; Kaestner KH
Mol Metab; 2021 Jul; 49():101193. PubMed ID: 33610858
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
Yu B; Dong C; Hu Z; Liu B
Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis.
Yu Y; Yang X; Tong K; Yin S; Hu G; Zhang F; Jiang P; Zhou M; Jian W
Front Cardiovasc Med; 2022; 9():1041044. PubMed ID: 36505359
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
Medicine (Baltimore); 2021 Feb; 100(7):e24873. PubMed ID: 33607862
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus: A meta-analysis.
Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
Medicine (Baltimore); 2021 Oct; 100(40):e27476. PubMed ID: 34622877
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of glucokinase activators for type 2 diabetes mellitus therapy: a meta-analysis of double-blind randomized controlled trials.
Qu Y; Wang K; Lin S; Cao L; Xu Z
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):914-922. PubMed ID: 33577046
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
